Mary L. Michaelis

Mary L. Michaelis

Auto-generated profile, based on publicly available information

Mary L. Michaelis

University of Kansas

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2005 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
MMM. L. Michaelis
M. L. Michaelis
SASabah Ansar
Sabah Ansar
YCY. Chen
Y. Chen
ERE. R. Reiff
E. R. Reiff
KSK. I. Seyb
K. I. Seyb
GGGunda I Georg
Gunda I Georg
Deposition of β-amyloid peptide (Aβ) and hyperphosphorylation of the τ protein are associated with neuronal dysfunction and cell death in Alzheimer's disease. Although the relationship between these two processes is not yet understood, studies have shown that both in vitro and in vivo exposure of neurons to Aβ leads to τ hyperphosphorylation and neuronal dystrophy. We previously reported that the microtubule-stabilizing drug paclitaxel (Taxol) protects primary neurons against toxicity induced by the Aβ25-35 peptide. The studies in this report were undertaken to characterize the actions of paclitaxel more fully, to assess the effectiveness of structurally diverse microtubulestabilizing agents in protecting neurons, and to determine the time course of the protective effects of the drugs. Primary neurons were exposed to Aβ in the presence or absence of several agents shown to interact with microtubules, and neuronal survival was monitored. Paclitaxel protected neurons against Aβ1-42 toxicity, and paclitaxel-treated cultures exposed to Aβ showed enhanced survival over Aβ-only cultures for several days. Neuronal apoptosis induced by Aβ was blocked by paclitaxel. Other taxanes and three structurally diverse microtubule-stabilizing compounds also significantly increased survival of Aβ-treated cultures. At concentrations below 100 nM, the drugs that protected the neurons did not produce detectable toxicity when added to the cultures alone. Although multiple mechanisms are likely to contribute to the neuronal cell death induced by oligomeric or fibrillar forms of Aβ, low concentrations of drugs that preserve the integrity of the cytoskeletal network may help neurons survive the toxic cascades initiated by these peptides.

19 February 2009 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
XWXinkun Wang
Xinkun Wang
AZAsma Zaidi
Asma Zaidi
RPRanu Pal
Ranu Pal
AGAlexander S Garrett
Alexander S Garrett
RBRogelio Braceras
Rogelio Braceras
EMElias K Michaelis
Elias K Michaelis
Oxidative stress (OS) is an important factor in brain aging and neurodegenerative diseases. Certain neurons in different brain regions exhibit selective vulnerability to OS. Currently little is known about the underlying mechanisms of this selective neuronal vulnerability. The purpose of this study was to identify endogenous factors that predispose vulnerable neurons to OS by employing genomic and biochemical approaches.

1 March 2003 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
MMMary L. Michaelis
Mary L. Michaelis
Enormous effort is now being devoted to developing drugs that slow neurodegeneration in Alzheimer's disease (AD), although insights into AD genetics and molecular pathogenesis only arose in the last 15 years. Acetylcholinesterase inhibitors that temporarily slow loss of cognitive function remain the only approved AD drugs. Discovery of mutations in three genes leading to severe early onset AD was critical in focusing attention on the role of amyloid peptides (Aβ) in neuronal cell death, and enhanced understanding of the biology of these peptides has led to an array of mechanism-based drug discovery strategies. These include inhibitors for Aβ-generating proteases, agents that prevent or reverse Aβ oligomerization, immunotherapies to reduce Aβ in brain and plasma, and drugs to modulate cholesterol-mediated effects on Aβ transport. Strategies are also underway to minimize toxic effects of Aβ fibrils on neurons, and these include antioxidants, blockers of glutamate-mediated excitotoxicity, and modulators of inflammatory responses within the brain. Although several approaches involve new agents for recently discovered targets, many are based on new applications of existing drugs such as statins and nonsteroidal anti-inflammatory drugs. Discovery of abnormally phosphorylated τ protein in neurofibrillary tangles in AD brain has led to strategies for identifying selective inhibitors of τ kinases and central nervous system/brain-permeable drugs that help maintain microtubule integrity. Clearly, a large gap exists between our understanding of the cellular cascades targeted in drug discovery and widespread failure of the nervous system that AD represents. Nevertheless, the pace of recent research clearly supports optimism that slowing progression of AD will soon be possible.

1 January 2002 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
MMMary L. Michaelis
Mary L. Michaelis
RDRick T. Dobrowsky
Rick T. Dobrowsky
GLGuibin Li
Guibin Li

1 January 2003 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
ARAntonie Rice
Antonie Rice
MMMary L. Michaelis
Mary L. Michaelis
GGGunda I Georg
Gunda I Georg
YLYanbin Liu
Yanbin Liu
BTBrandon Turunen
Brandon Turunen
KAKenneth L. Audus
Kenneth L. Audus

1 January 2006 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
KSKathleen I. Seyb
Kathleen I. Seyb
SASabah Ansar
Sabah Ansar
JBJennifer Bean
Jennifer Bean
MMMary L. Michaelis
Mary L. Michaelis